Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Glioblastoma × palbociclib × Clear all

Phase

Phase EARLY_PHASE1 1 Phase 2 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 15 Squamous Cell Carcinoma of Head and Neck 2 Neoplasm Metastasis 2 Melanoma 2 Endometrial Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Breast Diseases 2 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Solid Tumors Refractory to Standard Therapy 1 Solid Tumors 1 Solid Tumor, Adult 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasms by Site 1 Neoplasms 1 Liposarcoma, Myxoid 1 Liposarcoma 1 Leukemia, Myeloid, Acute 1 Kidney Neoplasms 1 Human Epidermal Growth Factor 2 Negative Carcinoma of Breast 1 Hereditary Sensory and Autonomic Neuropathies 1 Head and Neck Neoplasms 1 HER2-positive Breast Cancer 1 Glioblastoma 1 Gastrointestinal Neoplasms 1 Fallopian Tube Neoplasms 1 Esophageal Neoplasms 1 ER+ HER2- Advanced Breast Cancer 1 EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor 1

Interventions

Temozolomide 65 Radiotherapy 26 Bevacizumab 23 Carboplatin 12 Radiation 11 pembrolizumab 10 Irinotecan 7 Carmustine 7 Surgical Procedures, Operative 6 Radiosurgery 6 Erlotinib Hydrochloride 6 Nivolumab 5 Everolimus 5 temsirolimus 4 atezolizumab 4 Vorinostat 4 Radiotherapy, Intensity-Modulated 4 Lomustine 4 Aminolevulinic Acid 4 tipifarnib 3 fludarabine 3 Sirolimus 3 Radiotherapy, Conformal 3 Paclitaxel 3 Magnetic Resonance Spectroscopy 3 IL13-PE38 3 Granulocyte-Macrophage Colony-Stimulating Factor 3 Gemcitabine 3 Drug Therapy 3 Cyclophosphamide 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03158389 2023-09-28

N²M²

University Hospital Heidelberg

Phase 1/2 Completed

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡